Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 2/2020

01-03-2020 | Breast Cancer | Original Article

Meta-analysis of deep inspiration breath hold (DIBH) versus free breathing (FB) in postoperative radiotherapy for left-side breast cancer

Authors: Junming Lai, Shuang Hu, Yongbiao Luo, Rikui Zheng, Qibao Zhu, Pingliang Chen, Beiyuan Chi, Yunhui Zhang, Fangyan Zhong, Xin Long

Published in: Breast Cancer | Issue 2/2020

Login to get access

Abstract

Objectives

This meta-analysis evaluates the difference in deep inspiration breath hold (DIBH) versus free breathing (FB) for patients receiving postoperative radiotherapy for left breast cancer and provides a useful reference for clinical practice.

Methods

The relevant controlled trials of DIBH versus FB in postoperative radiotherapy for left-side breast cancer were retrieved from the databases of PubMed, Science Direct, Cochrane Library, and Web of Science databases. The principal outcome of interest was heart dose, left anterior descending coronary artery (LADCA) dose, and left lung dose and target coverage. We calculated summary standardized mean difference (SMD) and 95% confidence intervals (CI). The meta-analysis was performed using RevMan 5.3 software.

Results

The analysis included 1019 patients from 12 observational studies, of which 576 cases were in the DIBH group and 443 cases in the FB group. Compared with the FB group, the DIBH group can have lower heart dose, left anterior descending coronary artery (LADCA) dose, and left lung dose more effectively, and the difference was statistically significant (heart dose, SMD = − 1.36, 95% CI − 1.64 ~ − 1.09, P < 0.01. LADCA dose, SMD = − 1.45, 95% CI − 1.62 ~ − 1.27, P < 0.01. Left lung dose, SMD = − 0.52, 95% CI − 0.81 ~ − 0.23, P < 0.01). There was no significant difference in target coverage between the two groups (SMD = 0.03, 95% CI − 0.11 ~ 0.18, P = 0.64).

Conclusion

By this meta-analysis, we found that implementation of DIBH in postoperative radiotherapy for left-side breast cancer can reduce irradiation of heart dose, LADCA dose and left lung dose, without compromising target coverage.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2016;67(1):277–300.
2.
Mcgale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.PubMedCrossRef
3.
Beadle BM, Woodward WA, Tucker SL, et al. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys. 2008;73(3):734–44.PubMedPubMedCentralCrossRef
4.
Cho BCJ, Schwarz M, Mijnheer BJ, et al. Simplified intensity-modulated radiotherapy using pre-defined segments to reduce cardiac complications in left-sided breast cancer. Radiother Oncol. 2004;70(3):231–41.PubMedCrossRef
5.
Senkus-Konefka E, Jassem J. Cardiovascular effects of breast cancer radiotherapy. Cancer Treat Rev. 2007;33(6):578–93.PubMedCrossRef
6.
Darby SC, Ewertz M, Mcgale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.PubMedCrossRef
7.
Darby SC, Mcgale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557–65.PubMedCrossRef
8.
Demirci S, Nam J, Hubbs JL, et al. Radiation-induced cardiac toxicity after therapy for breast cancer: interaction between treatment era and follow-up duration. Int J Radiat Oncol Biol Phys. 2009;73(4):980–7.PubMedCrossRef
9.
Henson KE, Mcgale P, Taylor C, et al. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br J Cancer. 2013;108(1):179–82.PubMedCrossRef
10.
Alderliesten T, Betgen A, Elkhuizen PHM, et al. Estimation of heart-position variability in 3D-surface-image-guided deep-inspiration breath-hold radiation therapy for left-sided breast cancer. Radiother Oncol. 2013;109(3):442–7.PubMedCrossRef
11.
Sixel KE, Aznar MC, Ung YC. Deep inspiration breath hold to reduce irradiated heart volume in breast cancer patients. Int J Radiat Oncol Biol Phys. 2001;49(1):199–204.PubMedCrossRef
12.
Pedersen AN, Korreman S, Nyström H, et al. Breathing adapted radiotherapy of breast cancer: reduction of cardiac and pulmonary doses using voluntary inspiration breath-hold. Radiother Oncol. 2004;72(1):53–60.PubMedCrossRef
13.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
14.
Shuster JJ. Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors. Res Synth Methods. 2011;2(2):126–30.CrossRef
15.
Feng Z, Jiayan S, Zhongjie L, et al. Abdominal DIBH reduces the cardiac dose even further: a prospective analysis. Radiother Oncol. 2018;13(1):116.
16.
Lawler G, Leech M. Dose sparing potential of deep inspiration breath-hold technique for left breast cancer radiotherapy organs-at-risk. Anticancer Res. 2017;37(2):883–90.PubMedCrossRef
17.
Kunheri B, Kotne S, Nair SS, et al. A dosimetric analysis of cardiac dose with or without active breath coordinator moderate deep inspiratory breath hold in left sided breast cancer radiotherapy. J Cancer Res Ther. 2017;13(1):56–61.PubMedCrossRef
18.
Mohamad O, Shiao J, Zhao B, Roach K, Ramirez E, Vo DT, et al. Deep inspiration breathhold for left-sided breast cancer patients with unfavorable cardiac anatomy requiring internal mammary nodal irradiation. Pract Radiat Oncol. 2017;7(6):e361–7.PubMedCrossRef
19.
Jensen CA, Abramova T, Frengen J, et al. Monitoring deep inspiration breath hold for left-sided localized breast cancer radiotherapy with an in-house developed laser distance meter system. J Appl Clin Med Phys. 2017;18(5):117–23.PubMedPubMedCentralCrossRef
20.
Eldredge-Hindy H, Lockamy V, Crawford A, Nettleton V, Werner-Wasik M, Siglin J, et al. Active Breathing Coordinator reduces radiation dose to the control in patients with left breast cancer: report of a prospective heart and preserves local trial. Pract Radiat Oncol. 2015;5(1):4–10.PubMedPubMedCentralCrossRef
21.
Rochet N, Drake JI, Harrington K, et al. Deep inspiration breath-hold technique in left-sided breast cancer radiation therapy: evaluating cardiac contact distance as a predictor of cardiac exposure for patient selection. Pract Radiat Oncol. 2015;5(3):e127–34.PubMedCrossRef
22.
Tanguturi SK, Lyatskaya Y, Chen Y, Catalano PJ, Chen MH, Yeo WP, et al. Prospective assessment of deep inspiration breath-hold using 3-dimensional surface tracking for irradiation of left-sided breast cancer. Pract Radiat Oncol. 2015;5(6):358–65.PubMedCrossRef
23.
Wiant D, Wentworth S, Liu H, Sintay B. How important is a reproducible breath hold for deep inspiration breath hold breast radiation therapy. Int J Radiat Oncol Biol Phys. 2015;93(4):901–7.PubMedCrossRef
24.
Comsa D, Barnett E, Le K, Mohamoud G, Zaremski D, Fenkell L, et al. Introduction of moderate deep inspiration breath hold for radiation therapy of left breast: initial experience of a regional cancer center. Pract Radiat Oncol. 2014;4(5):298–305.PubMedCrossRef
25.
Nissen HD, Appelt AL. Improved heart, lung and target dose with deep inspiration breath hold in a large clinical series of breast cancer patients. Radiother Oncol. 2013;106(1):28–32.PubMedCrossRef
26.
Vikström J, Hjelstuen MHB, Mjaaland I, et al. Cardiac and pulmonary dose reduction for tangentially irradiated breast cancer, utilizing deep inspiration breath-hold with audio-visual guidance, without compromising target coverage. Acta Oncol. 2011;50(1):42–50.PubMedCrossRef
27.
Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16.PubMedCrossRef
28.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.PubMedCrossRef
29.
Taylor CW, Nisbet A, Mcgale P, et al. Cardiac doses from Swedish breast cancer radiotherapy since the 1950s. Radiother Oncol. 2009;90(1):127–35.PubMedCrossRef
30.
Jagsi R, Griffith KA, Koelling T, et al. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650–7.PubMedCrossRef
31.
Correa CR, Litt HI, Hwang WT, et al. Coronary artery findings after left-sided compared with right-sided radiation treatment for early-stage breast cancer. J Clin Oncol. 2007;25(21):3031–7.PubMedCrossRef
32.
Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656–65.PubMedPubMedCentralCrossRef
33.
Mulliez T, Veldeman L, Speleers B, et al. Heart dose reduction by prone deep inspiration breath hold in left-sided breast irradiation. Radiother Oncol. 2015;114(1):79–84.PubMedCrossRef
34.
Cox JD, Stetz JA, Pajak TF. Toxicity Criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.PubMedCrossRef
35.
Goldman UB, Wennberg B, Svane G, et al. Reduction of radiation pneumonitis by V20-constraints in breast cancer. Radiat Oncol. 2010;5(1):99.PubMedCentralCrossRef
36.
Blom Goldman U, Anderson M, Wennberg B, et al. Radiation pneumonitis and pulmonary function with lung dose–volume constraints in breast cancer irradiation. J Radiother Pract. 2014;13(02):211–7.PubMedCrossRef
37.
Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85(2):444–50.PubMedCrossRef
Metadata
Title
Meta-analysis of deep inspiration breath hold (DIBH) versus free breathing (FB) in postoperative radiotherapy for left-side breast cancer
Authors
Junming Lai
Shuang Hu
Yongbiao Luo
Rikui Zheng
Qibao Zhu
Pingliang Chen
Beiyuan Chi
Yunhui Zhang
Fangyan Zhong
Xin Long
Publication date
01-03-2020
Publisher
Springer Japan
Published in
Breast Cancer / Issue 2/2020
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-019-01023-9

Other articles of this Issue 2/2020

Breast Cancer 2/2020 Go to the issue

Original Article

Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer

Original Article

A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer

Original Article

Effects of a structured group intervention on obesity among breast cancer survivors

Original Article

Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines

Review Article

Prevalence of anxiety among breast cancer patients: a systematic review and meta-analysis

Original Article

kOBCS©: a novel software calculator program of the Objective Breast Cosmesis Scale (OBCS)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits